Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment
The dose makes the poison, the common motto of toxicology first expressed by Paracelsus more than 400 years ago, may effectively serve to guide potential applications for metformin and related biguanides in oncology. While Paracelsus' law for the dose-response effect has been commonly exploited...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2014 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:10256/9215 |
| Acceso en línea: | http://hdl.handle.net/10256/9215 |
| Access Level: | acceso abierto |
| Palabra clave: | Metformina Diabetis Càncer Metformin Diabetes Cancer Cáncer |
| id |
ES_f2d80fe338a9e02fe288b228f5dfd67b |
|---|---|
| oai_identifier_str |
oai:recercat.cat:10256/9215 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatmentMenéndez Menéndez, Javier AbelQuirantes Piné, RosaRodríguez Gallego, EstherCufí González, SílviaCorominas Faja, BrunaCuyàs, ElisabetBosch Barrera, JoaquimMartin Castillo, BegoñaSegura Carretero, AntonioJoven, JorgeMetforminaDiabetisCàncerMetforminDiabetesCancerMetforminDiabetesCáncerThe dose makes the poison, the common motto of toxicology first expressed by Paracelsus more than 400 years ago, may effectively serve to guide potential applications for metformin and related biguanides in oncology. While Paracelsus' law for the dose-response effect has been commonly exploited for the use of some anti-cancer drugs at lower doses in non-neoplastic diseases (e.g., methotrexate), the opposite scenario also holds true; in other words, higher doses of non-oncology drugs, such as anti-diabetic biguanides, might exert direct anti-neoplastic effects. Here, we propose that, as for any drug, there is a dose range for biguanides that is without any effect, one corresponding to"diabetobiguanides" with a pharmacological effect (e.g., insulin sensitization in type 2 diabetes, prevention of insulin-dependent carcinogenesis, indirect inhibition of insulin and growth factor-dependent cancer growth) but with minimal toxicity and another corresponding to 'oncobiguanides' with pharmacological (i.e., direct and strong anticancer activity against cancer cells) as well as toxic effects. Considering that biguanides demonstrate a better safety profile than most oncology drugs in current use, we should contemplate the possibility of administering biguanides through non-conventional routes (e.g., inhaled for carcinomas of the lung, topical for skin cancers, intravenous as an adjunctive therapy, rectal suppositories for rectal cancer) to unambiguously investigate the therapeutic value of high-dose transient biguanide exposure in cancer. Perhaps then, the oncobiguanides, as we call them here, could be viewed as a mechanistically different type of anti-cancer drugs employed at doses notably higher than those used chronically when functioning as diabetobiguanidesImpact Journals2014info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion5 p.application/pdfhttp://hdl.handle.net/10256/9215http://hdl.handle.net/10256/9215Oncotarget, 2014, vol. 5, núm. 9, p. 2344-2348Menéndez, Javier A. Quirantes-Piné, Rosa Rodríguez-Gallego, Esther Cufí, Sílvia Corominas-Faja, Bruna Cuyàs, Elisabet Bosch-Barrera, Joaquim Martin-Castillo, Begoña Segura-Carretero, Antonio Joven, Jorge 2014 Oncobiguanides: Paracelsus" law and nonconventional routes for administering diabetobiguanides for cancer treatment Oncotarget 5 9 2344 2348reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)Inglésinfo:eu-repo/semantics/altIdentifier/issn/1949-2553Reconeixement 3.0 Espanyahttp://creativecommons.org/licenses/by/3.0/es/deed.cainfo:eu-repo/semantics/openAccessoai:recercat.cat:10256/92152026-05-29T05:05:01Z |
| dc.title.none.fl_str_mv |
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment |
| title |
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment |
| spellingShingle |
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment Menéndez Menéndez, Javier Abel Metformina Diabetis Càncer Metformin Diabetes Cancer Metformin Diabetes Cáncer |
| title_short |
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment |
| title_full |
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment |
| title_fullStr |
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment |
| title_full_unstemmed |
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment |
| title_sort |
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment |
| dc.creator.none.fl_str_mv |
Menéndez Menéndez, Javier Abel Quirantes Piné, Rosa Rodríguez Gallego, Esther Cufí González, Sílvia Corominas Faja, Bruna Cuyàs, Elisabet Bosch Barrera, Joaquim Martin Castillo, Begoña Segura Carretero, Antonio Joven, Jorge |
| author |
Menéndez Menéndez, Javier Abel |
| author_facet |
Menéndez Menéndez, Javier Abel Quirantes Piné, Rosa Rodríguez Gallego, Esther Cufí González, Sílvia Corominas Faja, Bruna Cuyàs, Elisabet Bosch Barrera, Joaquim Martin Castillo, Begoña Segura Carretero, Antonio Joven, Jorge |
| author_role |
author |
| author2 |
Quirantes Piné, Rosa Rodríguez Gallego, Esther Cufí González, Sílvia Corominas Faja, Bruna Cuyàs, Elisabet Bosch Barrera, Joaquim Martin Castillo, Begoña Segura Carretero, Antonio Joven, Jorge |
| author2_role |
author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Metformina Diabetis Càncer Metformin Diabetes Cancer Metformin Diabetes Cáncer |
| topic |
Metformina Diabetis Càncer Metformin Diabetes Cancer Metformin Diabetes Cáncer |
| description |
The dose makes the poison, the common motto of toxicology first expressed by Paracelsus more than 400 years ago, may effectively serve to guide potential applications for metformin and related biguanides in oncology. While Paracelsus' law for the dose-response effect has been commonly exploited for the use of some anti-cancer drugs at lower doses in non-neoplastic diseases (e.g., methotrexate), the opposite scenario also holds true; in other words, higher doses of non-oncology drugs, such as anti-diabetic biguanides, might exert direct anti-neoplastic effects. Here, we propose that, as for any drug, there is a dose range for biguanides that is without any effect, one corresponding to"diabetobiguanides" with a pharmacological effect (e.g., insulin sensitization in type 2 diabetes, prevention of insulin-dependent carcinogenesis, indirect inhibition of insulin and growth factor-dependent cancer growth) but with minimal toxicity and another corresponding to 'oncobiguanides' with pharmacological (i.e., direct and strong anticancer activity against cancer cells) as well as toxic effects. Considering that biguanides demonstrate a better safety profile than most oncology drugs in current use, we should contemplate the possibility of administering biguanides through non-conventional routes (e.g., inhaled for carcinomas of the lung, topical for skin cancers, intravenous as an adjunctive therapy, rectal suppositories for rectal cancer) to unambiguously investigate the therapeutic value of high-dose transient biguanide exposure in cancer. Perhaps then, the oncobiguanides, as we call them here, could be viewed as a mechanistically different type of anti-cancer drugs employed at doses notably higher than those used chronically when functioning as diabetobiguanides |
| publishDate |
2014 |
| dc.date.none.fl_str_mv |
2014 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10256/9215 http://hdl.handle.net/10256/9215 |
| url |
http://hdl.handle.net/10256/9215 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/issn/1949-2553 |
| dc.rights.none.fl_str_mv |
Reconeixement 3.0 Espanya http://creativecommons.org/licenses/by/3.0/es/deed.ca info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Reconeixement 3.0 Espanya http://creativecommons.org/licenses/by/3.0/es/deed.ca |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
5 p. application/pdf |
| dc.publisher.none.fl_str_mv |
Impact Journals |
| publisher.none.fl_str_mv |
Impact Journals |
| dc.source.none.fl_str_mv |
Oncotarget, 2014, vol. 5, núm. 9, p. 2344-2348 Menéndez, Javier A. Quirantes-Piné, Rosa Rodríguez-Gallego, Esther Cufí, Sílvia Corominas-Faja, Bruna Cuyàs, Elisabet Bosch-Barrera, Joaquim Martin-Castillo, Begoña Segura-Carretero, Antonio Joven, Jorge 2014 Oncobiguanides: Paracelsus" law and nonconventional routes for administering diabetobiguanides for cancer treatment Oncotarget 5 9 2344 2348 reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str |
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| reponame_str |
Recercat. Dipósit de la Recerca de Catalunya |
| collection |
Recercat. Dipósit de la Recerca de Catalunya |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869424320490504192 |
| score |
15.811543 |